Limits...
Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature.

Kelliny M, Croarkin PE, Moore KM, Bobo WV - Ther Clin Risk Manag (2015)

Bottom Line: This article reviews the pharmacological profile and available efficacy and tolerability/safety data for vortioxetine, one of the most recent antidepressant drugs to be approved in the USA for the treatment of major depressive disorder (MDD) in adults.Nevertheless, effectiveness studies that directly compare the clinical effects of vortioxetine with other established antidepressant drugs are lacking, and there is no evidence as yet that vortioxetine is more clinically effective than other types of antidepressants.Some preliminary suggestions concerning the place of vortioxetine among the broad range of pharmacological treatments for adults with MDD are provided.

View Article: PubMed Central - PubMed

Affiliation: Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.

ABSTRACT
This article reviews the pharmacological profile and available efficacy and tolerability/safety data for vortioxetine, one of the most recent antidepressant drugs to be approved in the USA for the treatment of major depressive disorder (MDD) in adults. The efficacy of vortioxetine for treating MDD in adults is supported by eight positive short-term (6- to 12-weeks) randomized, placebo-controlled trials, and one positive randomized, double-blind, 52-week relapse prevention trial. Based on pooled data from short-term randomized trials and from longer-term studies, vortioxetine appears to be well tolerated and to have a low incidence of adverse effects on sexual functioning. Vortioxetine also appears to be effective for treating symptoms of MDD in the elderly based on the results of one randomized trial for which recruitment was focused on this specific population. Nevertheless, effectiveness studies that directly compare the clinical effects of vortioxetine with other established antidepressant drugs are lacking, and there is no evidence as yet that vortioxetine is more clinically effective than other types of antidepressants. Some preliminary suggestions concerning the place of vortioxetine among the broad range of pharmacological treatments for adults with MDD are provided.

No MeSH data available.


Related in: MedlinePlus

Frequency of selected adverse effects on sexual functioning, based on pooled data from short-term randomized trials of vortioxetine in adults with major depression.Notes: This graph displays the pooled sex-specific frequencies of treatment-emergent adverse effects on sexual performance by spontaneous self-report and according to Arizona Sexual Experiences Scale scores, as reported in the vortioxetine drug label.Abbreviation: ASEX, Arizona Sexual Experiences Scale.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4542474&req=5

f3-tcrm-11-1193: Frequency of selected adverse effects on sexual functioning, based on pooled data from short-term randomized trials of vortioxetine in adults with major depression.Notes: This graph displays the pooled sex-specific frequencies of treatment-emergent adverse effects on sexual performance by spontaneous self-report and according to Arizona Sexual Experiences Scale scores, as reported in the vortioxetine drug label.Abbreviation: ASEX, Arizona Sexual Experiences Scale.

Mentions: Treatment-emergent sexual dysfunction is reviewed separately given how frequently it leads to poor adherence to antidepressants.70–72 A summary of pooled data on self-reported adverse effects of vortioxetine on sexual desire, performance, and satisfaction, as well as systematic measurement of sexual effects of treatment using the Arizona Sexual Experiences Scale (ASEX),73 has been provided in the vortioxetine drug label (Figure 3).45 For men, the incidence of self-reported adverse effects related to sexual dysfunction while being treated with vortioxetine ranged from 3% at 5 mg/day to 5% at 20 mg/day, compared with 2% for placebo. For women, the incidence of self-reported sexual adverse effects with vortioxetine ranged from <1% at 5 mg/day to 2% at 20 mg/day, compared with <1% for placebo.


Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature.

Kelliny M, Croarkin PE, Moore KM, Bobo WV - Ther Clin Risk Manag (2015)

Frequency of selected adverse effects on sexual functioning, based on pooled data from short-term randomized trials of vortioxetine in adults with major depression.Notes: This graph displays the pooled sex-specific frequencies of treatment-emergent adverse effects on sexual performance by spontaneous self-report and according to Arizona Sexual Experiences Scale scores, as reported in the vortioxetine drug label.Abbreviation: ASEX, Arizona Sexual Experiences Scale.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4542474&req=5

f3-tcrm-11-1193: Frequency of selected adverse effects on sexual functioning, based on pooled data from short-term randomized trials of vortioxetine in adults with major depression.Notes: This graph displays the pooled sex-specific frequencies of treatment-emergent adverse effects on sexual performance by spontaneous self-report and according to Arizona Sexual Experiences Scale scores, as reported in the vortioxetine drug label.Abbreviation: ASEX, Arizona Sexual Experiences Scale.
Mentions: Treatment-emergent sexual dysfunction is reviewed separately given how frequently it leads to poor adherence to antidepressants.70–72 A summary of pooled data on self-reported adverse effects of vortioxetine on sexual desire, performance, and satisfaction, as well as systematic measurement of sexual effects of treatment using the Arizona Sexual Experiences Scale (ASEX),73 has been provided in the vortioxetine drug label (Figure 3).45 For men, the incidence of self-reported adverse effects related to sexual dysfunction while being treated with vortioxetine ranged from 3% at 5 mg/day to 5% at 20 mg/day, compared with 2% for placebo. For women, the incidence of self-reported sexual adverse effects with vortioxetine ranged from <1% at 5 mg/day to 2% at 20 mg/day, compared with <1% for placebo.

Bottom Line: This article reviews the pharmacological profile and available efficacy and tolerability/safety data for vortioxetine, one of the most recent antidepressant drugs to be approved in the USA for the treatment of major depressive disorder (MDD) in adults.Nevertheless, effectiveness studies that directly compare the clinical effects of vortioxetine with other established antidepressant drugs are lacking, and there is no evidence as yet that vortioxetine is more clinically effective than other types of antidepressants.Some preliminary suggestions concerning the place of vortioxetine among the broad range of pharmacological treatments for adults with MDD are provided.

View Article: PubMed Central - PubMed

Affiliation: Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.

ABSTRACT
This article reviews the pharmacological profile and available efficacy and tolerability/safety data for vortioxetine, one of the most recent antidepressant drugs to be approved in the USA for the treatment of major depressive disorder (MDD) in adults. The efficacy of vortioxetine for treating MDD in adults is supported by eight positive short-term (6- to 12-weeks) randomized, placebo-controlled trials, and one positive randomized, double-blind, 52-week relapse prevention trial. Based on pooled data from short-term randomized trials and from longer-term studies, vortioxetine appears to be well tolerated and to have a low incidence of adverse effects on sexual functioning. Vortioxetine also appears to be effective for treating symptoms of MDD in the elderly based on the results of one randomized trial for which recruitment was focused on this specific population. Nevertheless, effectiveness studies that directly compare the clinical effects of vortioxetine with other established antidepressant drugs are lacking, and there is no evidence as yet that vortioxetine is more clinically effective than other types of antidepressants. Some preliminary suggestions concerning the place of vortioxetine among the broad range of pharmacological treatments for adults with MDD are provided.

No MeSH data available.


Related in: MedlinePlus